Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2018, Article ID 8065691, 7 pages
https://doi.org/10.1155/2018/8065691
Clinical Study

Factors Influencing Hemoglobin Variability and Its Association with Mortality in Hemodialysis Patients

1Department of Nephrology, Ankara Training and Research Hospital, Ankara, Turkey
2Dr. Nafiz Korez State Hospital, Ankara, Turkey
3Department of Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey
4Department of Nephrology, Baskent University Faculty of Medicine, Istanbul, Turkey

Correspondence should be addressed to Suleyman Karakose; moc.oohay@esokaraknamyelus

Received 6 October 2017; Revised 25 December 2017; Accepted 11 January 2018; Published 1 April 2018

Academic Editor: Allen R. Nissenson

Copyright © 2018 Zeynep Bal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Ritz, M. Laville, R. W. Bilous et al., “Target Level for Hemoglobin Correction in Patients With Diabetes and CKD: Primary Results of the Anemia Correction in Diabetes (ACORD) Study,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 194–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Laupacis, C. Wong, and D. Churchill, “The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin,” Controlled Clinical Trials, vol. 12, no. 4, pp. S168–S179, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Locatelli, P. Aljama, P. Barany et al., Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure, vol. 19, supplement 2, Nephrol Dial Transplant, ii1–ii47, 2004.
  4. A. L. de Francisco, P. Stenvinkel, and S. Vaulont, “Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness,” NDT Plus, vol. 2, no. Supplement 1, pp. i18–i26, 2009. View at Publisher · View at Google Scholar
  5. K. Kalantar-Zadeh and G. R. Aronoff, “Hemoglobin variability in anemia of chronic kidney disease,” Journal of the American Society of Nephrology, vol. 20, no. 3, pp. 479–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Lacson Jr., N. Ofsthun, and J. M. Lazarus, “Effect of variability in anemia management on hemoglobin outcomes in ESRD,” American Journal of Kidney Diseases, vol. 41, no. 1, pp. 111–124, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Ebben, D. T. Gilbertson, R. N. Foley, and A. J. Collins, “Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.,” Clinical journal of the American Society of Nephrology : CJASN, vol. 1, no. 6, pp. 1205–1210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Kalantar-Zadeh, J. D. Kopple, G. Block, and M. H. Humphreys, “A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients,” American Journal of Kidney Diseases, vol. 38, no. 6, pp. 1251–1263, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. D. T. Gilbertson, Y. Peng, B. Bradbury, J. P. Ebben, and A. J. Collins, “Hemoglobin loevel variability: Anemia management among variability groups,” American Journal of Nephrology, vol. 30, no. 6, pp. 491–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Hung, H. Chen, K. Chen et al., “Hemoglobin variability does not predict mortality in peritoneal dialysis patients,” Biomedical Journal, vol. 35, no. 1, p. 79, 2012. View at Publisher · View at Google Scholar
  11. S. Fishbane and J. S. Berns, “Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin,” Kidney International, vol. 68, no. 3, pp. 1337–1343, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Portol'es, A. de Francisco, and J. L. Gorriz, “Haemoglobin variability in European HD patients is related to ESAs type, doses adjustments and clinical events more than to a regular cycling [abstract SP371],” in Proceedings of the ERA-EDTA, Stockholm, Sweden, 2008.
  13. J. K. Inrig, H. X. Barnhart, D. Reddan et al., “Effect of hemoglobin target on progression of kidney disease: A secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial,” American Journal of Kidney Diseases, vol. 60, no. 3, pp. 390–401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Skali, J. Lin, M. A. Pfeffer et al., “Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm,” American Journal of Kidney Diseases, vol. 61, no. 2, pp. 238–246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. W. F. Owen and E. G. Lowrie, “C-reactive protein as an outcome predictor for maintenance hemodialysis patients,” Kidney International, vol. 54, no. 2, pp. 627–636, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Dellanna, G. R. Hetzel, and G. Backus, “Hb-variation in ESRD patients—association between risk factors and ESA dose [abstract SA-PO028],” in Proceedings of the American Society of Nephrology Annual Congress, San Diego , USA, 2006.
  17. P. Barany, J. J. Carrero, and S. Snaedal J'onsd'ottir, “Variability of hemoglobin (Hb) levels in relation to inflammatory status and iron metabolism in hemodialysis (HD) patients (Pts),” in Proceedings of the American Society of Nephrology Annual Congress, San Diego , USA, 2006.
  18. K. Kalantar-Zadeh, R. A. Rodriguez, and M. H. Humphreys, “Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients,” Nephrology Dialysis Transplantation , vol. 19, no. 1, pp. 141–149, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Fiedler, P. M. Jehle, B. Osten, O. Dorligschaw, and M. Girndt, “Clinical nutrition scores are superior for the prognosis of haemodialysis patients compared to lab markers and bioelectrical impedance,” Nephrology Dialysis Transplantation , vol. 24, no. 12, pp. 3812–3817, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Koulouridis, M. Alfayez, T. A. Trikalinos, E. M. Balk, and B. L. Jaber, “Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis,” American Journal of Kidney Diseases, vol. 61, no. 1, pp. 44–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K.-U. Eckardt, J. Kim, F. Kronenberg et al., “Hemoglobin variability does not predict mortality in european hemodialysis patients,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1765–1775, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. D. T. Gilbertson, J. P. Ebben, R. N. Foley, E. D. Weinhandl, B. D. Bradbury, and A. J. Collins, “Hemoglobin level variability: Associations with mortality,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 133–138, 2008. View at Publisher · View at Google Scholar · View at Scopus